Literature DB >> 19658100

Phosphorylation of the SSBP2 and ABL proteins by the ZNF198-FGFR1 fusion kinase seen in atypical myeloproliferative disorders as revealed by phosphopeptide-specific MS.

Chitta Kasyapa1, Ting-Lei Gu, Lalitha Nagarajan, Lalitha Natarajan, Roberto Polakiewicz, John K Cowell.   

Abstract

The ZNF198-fibroblast growth factor receptor-1 (FGFR1) fusion kinase is a constitutively activated tyrosine kinase associated with a specific atypical myeloproliferative disease. The chimeric protein localizes to the cytoplasm, unlike the wild type FGFR1 receptor kinase, and presumably inappropriately phosphorylates specific targets as part of the oncogenic signaling cascade. Other than known targets of the FGFR1 kinase itself, few specific targets of ZNF198-FGFR1 have been identified. Using a genetically engineered HEK 293 cell system, we have identified proteins that are specifically phosphorylated in the presence of the fusion kinase using anti-phosphotyrosine immunoprecipitation and MS. Compared with 293 cells expressing exongenous wild type FGFR1, ZNF198-FGFR1 is associated with phosphorylation of several proteins including SSBP2, ABL, FLJ14235, CALM and TRIM4 proteins. The specificity of the phosphorylation events in the SSBP2 and ABL proteins, which have previously been implicated in leukemogenesis, was further confirmed independently using immunoprecipitation with protein-specific antibodies and Western blotting. The MS analysis also identified the phosphorylation events in the ZNF198 moiety in the chimeric protein that might be related to its function. These studies identify the intersection of several different leukemia-related pathways in the development of this myeloproliferative disorder and provide new insights into the substrates of FGFR1 under defined conditions.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19658100      PMCID: PMC2996822          DOI: 10.1002/pmic.200800852

Source DB:  PubMed          Journal:  Proteomics        ISSN: 1615-9853            Impact factor:   3.984


  38 in total

Review 1.  The Abl family kinases: mechanisms of regulation and signaling.

Authors:  Ann Marie Pendergast
Journal:  Adv Cancer Res       Date:  2002       Impact factor: 6.242

2.  ZNF198-FGFR1 transforms Ba/F3 cells to growth factor independence and results in high level tyrosine phosphorylation of STATS 1 and 5.

Authors:  D Smedley; A Demiroglu; M Abdul-Rauf; C Heath; C Cooper; J Shipley; N C Cross
Journal:  Neoplasia       Date:  1999-10       Impact factor: 5.715

3.  Endogenous retroviral sequence is fused to FGFR1 kinase in the 8p12 stem-cell myeloproliferative disorder with t(8;19)(p12;q13.3).

Authors:  Géraldine Guasch; Cornel Popovici; Francine Mugneret; Max Chaffanet; Pierre Pontarotti; Daniel Birnbaum; Marie-Josèphe Pébusque
Journal:  Blood       Date:  2002-06-28       Impact factor: 22.113

4.  Expression profiling of CD34+ hematopoietic stem/ progenitor cells reveals distinct subtypes of therapy-related acute myeloid leukemia.

Authors:  Zhijian Qian; Anthony A Fernald; Lucy A Godley; Richard A Larson; Michelle M Le Beau
Journal:  Proc Natl Acad Sci U S A       Date:  2002-11-04       Impact factor: 11.205

5.  FGFR1 is fused to the centrosome-associated protein CEP110 in the 8p12 stem cell myeloproliferative disorder with t(8;9)(p12;q33).

Authors:  G Guasch; G J Mack; C Popovici; N Dastugue; D Birnbaum; J B Rattner; M J Pébusque
Journal:  Blood       Date:  2000-03-01       Impact factor: 22.113

6.  The t(8;22) in chronic myeloid leukemia fuses BCR to FGFR1: transforming activity and specific inhibition of FGFR1 fusion proteins.

Authors:  A Demiroglu; E J Steer; C Heath; K Taylor; M Bentley; S L Allen; P Koduru; J P Brody; G Hawson; R Rodwell; M L Doody; F Carnicero; A Reiter; J M Goldman; J V Melo; N C Cross
Journal:  Blood       Date:  2001-12-15       Impact factor: 22.113

7.  Ssdp proteins interact with the LIM-domain-binding protein Ldb1 to regulate development.

Authors:  Lan Chen; Daniel Segal; Neil A Hukriede; Alexandre V Podtelejnikov; Dashzeveg Bayarsaihan; James A Kennison; Vasily V Ogryzko; Igor B Dawid; Heiner Westphal
Journal:  Proc Natl Acad Sci U S A       Date:  2002-10-15       Impact factor: 11.205

8.  Ssdp proteins bind to LIM-interacting co-factors and regulate the activity of LIM-homeodomain protein complexes in vivo.

Authors:  Donald J van Meyel; John B Thomas; Alan D Agulnick
Journal:  Development       Date:  2003-05       Impact factor: 6.868

9.  ssDNA-binding protein 2 is frequently hypermethylated and suppresses cell growth in human prostate cancer.

Authors:  Jun-Wei Liu; Jatin K Nagpal; Wenyue Sun; Juna Lee; Myoung Sook Kim; Kimberly L Ostrow; Shaoyu Zhou; Carmen Jeronimo; Rui Henrique; Wim Van Criekinge; Chu So Moon; Joseph A Califano; Barry Trink; David Sidransky
Journal:  Clin Cancer Res       Date:  2008-06-15       Impact factor: 12.531

Review 10.  Phosphorylation of calmodulin. Functional implications.

Authors:  Gustavo Benaim; Antonio Villalobo
Journal:  Eur J Biochem       Date:  2002-08
View more
  4 in total

Review 1.  Why and how to investigate the role of protein phosphorylation in ZIP and ZnT zinc transporter activity and regulation.

Authors:  T E Thingholm; L Rönnstrand; P A Rosenberg
Journal:  Cell Mol Life Sci       Date:  2020-02-19       Impact factor: 9.261

Review 2.  Why Be One Protein When You Can Affect Many? The Multiple Roles of YB-1 in Lung Cancer and Mesothelioma.

Authors:  Thomas G Johnson; Karin Schelch; Sunali Mehta; Andrew Burgess; Glen Reid
Journal:  Front Cell Dev Biol       Date:  2019-10-01

Review 3.  YB-1 as an Oncoprotein: Functions, Regulation, Post-Translational Modifications, and Targeted Therapy.

Authors:  Qiyan Yin; Min Zheng; Qianmei Luo; Dewei Jiang; Huifeng Zhang; Ceshi Chen
Journal:  Cells       Date:  2022-04-04       Impact factor: 6.600

Review 4.  Role of post-translational modification of the Y box binding protein 1 in human cancers.

Authors:  Lakshmi Prabhu; Antja-Voy Hartley; Matthew Martin; Fadumo Warsame; Emily Sun; Tao Lu
Journal:  Genes Dis       Date:  2015-05-27
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.